Current Document Type: HighlightsVideoPage Tiffany Richards, PhD, ANP-BC, AOCNP, on Newly Diagnosed Multiple Myeloma: Findings on DARA + VRd vs. VRd Alone - JADPRO

Watch More Highlights

Tiffany Richards, PhD, ANP-BC, AOCNP®, of The University of Texas MD Anderson Cancer Center, examines daratumumab (DARA) plus bortezomib, lenalidomide, and dexamethasone (VRd) vs. VRd alone in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant. DARA plus VRd significantly improved progression-free survival and increased the depth of response (LBA-1).

Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.